Skip to main content
Clinical Trials/NCT04154124
NCT04154124
Unknown
Not Applicable

Applying PET/MR in Rectal Cancer.

Tel-Aviv Sourasky Medical Center0 sites20 target enrollmentNovember 23, 2019
ConditionsRectal Cancer

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Rectal Cancer
Sponsor
Tel-Aviv Sourasky Medical Center
Enrollment
20
Primary Endpoint
Number of patient that shown the different between diagnostic value of single PET/MR scan in RC staging and compare it to that of MRI alone, PET/CT alone, and combined MRI and PET/CT
Last Updated
6 years ago

Overview

Brief Summary

The use of the novel recently introduced PET/MR scanner is believed to be promising in RC management, providing great anatomical details and detailed metabolic characterization. Preliminary data indicate it may become a strong imaging modality for staging of RC and has the potential to be used as a predictive tool guiding individualized therapy in patients receiving nT, but confirmation on prospective studies is mandatory. The use of radiomics as analysis approach may assist in achieving a better understanding of the obtained image data, and thus a more accurate disease assessment.

Objectives

  1. To preliminary assess the potential diagnostic value of single PET/MR scan in RC staging and compare it to that of MRI alone, PET/CT alone, and combined MRI and PET/CT.
  2. To preliminary assess the potential value of PET/MR in predicting pMR to nT.
  3. To use radiomics analysis of PET/MR data to develop a quantification clinical tools that allow a more accurate and comprehensive assessment of RC patients.
Registry
clinicaltrials.gov
Start Date
November 23, 2019
End Date
December 23, 2021
Last Updated
6 years ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • 1.Patients with newly diagnosed RC; histopathological confirmation of adenocarcinoma of colorectal origin.

Exclusion Criteria

  • Patients younger than 18 years;
  • other known active malignancy;
  • previous chemotherapy or radiotherapy;
  • previous pelvic operation;
  • patient that no intent / not suited for neoadjuvant therapy (including metastatic disease at presentation); contraindication to intravenous contrast agents.

Outcomes

Primary Outcomes

Number of patient that shown the different between diagnostic value of single PET/MR scan in RC staging and compare it to that of MRI alone, PET/CT alone, and combined MRI and PET/CT

Time Frame: 1 year

Similar Trials